See more : Bank of Ayudhya Public Company Limited (BAY-R.BK) Income Statement Analysis – Financial Results
Complete financial analysis of PsyBio Therapeutics Corp. (PSYBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PsyBio Therapeutics Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Atlas Arteria Limited (ALX.AX) Income Statement Analysis – Financial Results
- BayCurrent Consulting, Inc. (6532.T) Income Statement Analysis – Financial Results
- LandMark Optoelectronics Corporation (3081.TWO) Income Statement Analysis – Financial Results
- Ming Yang Smart Energy Group Limited (601615.SS) Income Statement Analysis – Financial Results
- VERBIO Vereinigte BioEnergie AG (VBVBF) Income Statement Analysis – Financial Results
PsyBio Therapeutics Corp. (PSYBF)
About PsyBio Therapeutics Corp.
PsyBio Therapeutics Corp., a biotechnology company, focuses on the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. The company is headquartered in Coconut Creek, Florida.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 50.00K | 62.50K | 1.53M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -50.00K | -62.50K | -1.53M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 390.14K | 622.80K | 54.55K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.95M | 8.90M | 991.94K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 3.85K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.95M | 8.90M | 4.85M | 38.97K | 20.86K | 39.85K | 77.04K |
| Other Expenses | 28.11K | 89.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.41M | 9.61M | 4.90M | 38.97K | 20.86K | 39.85K | 77.04K |
| Cost & Expenses | 4.55M | 9.67M | 6.44M | 38.97K | 20.86K | 39.85K | 77.04K |
| Interest Income | 6.56K | 31.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 21.05K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 146.05K | 9.04M | 6.44M | 171.86K | 161.14K | 0.00 | 0.00 |
| EBITDA | -4.53M | 0.00 | 0.00 | -16.16K | -20.86K | -39.85K | -77.04K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.55M | -8.23M | -6.44M | -38.97K | -20.86K | -39.85K | -77.04K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -331.34K | -1.98M | 353.00 | 22.81K | -1.00 | -3.00 | 20.18K |
| Income Before Tax | -4.89M | -11.02M | -6.44M | -16.16K | -20.86K | -39.85K | -56.86K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.43M | 0.35 | -171.86K | -161.14K | 0.00 | 0.00 |
| Net Income | -4.89M | -11.02M | -6.44M | -16.16K | -20.86K | -39.85K | -56.86K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.10 | -0.20 | 0.00 | -0.01 | -0.02 | -0.04 |
| EPS Diluted | -0.04 | -0.10 | -0.20 | 0.00 | -0.01 | -0.02 | -0.04 |
| Weighted Avg Shares Out | 111.81M | 106.94M | 31.59M | 0.00 | 2.36M | 2.33M | 1.44M |
| Weighted Avg Shares Out (Dil) | 111.81M | 106.94M | 31.59M | 0.00 | 2.36M | 2.33M | 1.44M |
PsyBio Therapeutics Awarded Approval to Manufacture Biosynthetic Tryptamines at Scale
PsyBio continues to develop psycho-targeted, biosynthesized tryptamines and with this authorization becomes the first biotechnology company to obtain government sanctioned, formal, written authorization to manufacture biosynthetic tryptamines including PsyBio-11142 at scale Oxford, Ohio and Denver, Colorado--(Newsfile Corp. - July 21,...
PsyBio Therapeutics successfully completes first pre-IND meeting with the FDA
PsyBio Therapeutics Corp has announced the successful completion of its initial pre-Investigational New Drug (IND) application meeting with the US Food and Drug Administration (FDA) as part of the regulatory submission process. The company said the focus of the pre-IND...
PsyBio Therapeutics presents 16 scientific abstracts highlighting its research and development efforts at two scientific conferences
PsyBio Therapeutics Corp said it presented 16 abstracts highlighting the biotechnology company's research and development initiatives at two scientific conferences. The abstracts covered topics such as biosynthetic pathway and transcriptional methodologic development; evaluation; screening and optimization of systems and organisms, and...
PsyBio Therapeutics shares updates on intellectual property and clinical development milestones
PsyBio Therapeutics Corp., a biotechnology company developing a portfolio of psychoactive compounds aimed at the treatment of mental health disorders, told shareholders that it has filed “six additional provisional manufacturing patent applications” to expand its intellectual property portfolio. The Oxford,...
PsyBio Therapeutics is developing psychoactive compounds which could be a mental health game changer
Has initiated pilot scale-up of its biosynthetic formulation of psilocybin Developing a bacterial biosynthesis process for tryptamine production Well capitalized in an oversubscribed raise What PsyBio Therapeutics does: PsyBio Therapeutics Corp (CVE:PSYB) is a biotechnology company developing a portfolio of...
PsyBio Therapeutics announces expansion of its intellectual property portfolio by filing six additional patent applications
PsyBio Therapeutics announced that it has filed six additional provisional manufacturing patent applications to expand its intellectual property portfolio. The Oxford, Ohio-based biotech company said that the new manufacturing patents cover a broad range of approaches to its biologic methodology...
PsyBio Therapeutics to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
OXFORD, Ohio and COCONUT CREEK, Fla., Oct. 11, 2021 /PRNewswire/ -- PsyBio Therapeutics Corp. (TSXV: PSYB, OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company developing novel, bespoke, approvable, psycho-targeted therapeutics to improve mental and neurological health, today...
PsyBio Therapeutics successfully demonstrates commercial-scale manufacturing feasibility
PsyBio Therapeutics Corp. reported that it has demonstrated the ability to manufacture PsyBio-11040, one of its first promising therapeutic candidates, at a commercial scale. The company said this is the result of numerous dedicated employees, consultants and contractors committing thousands...
PsyBio Therapeutics submits its first pre-IND application meeting request to FDA
PsyBio Therapeutics Corp. has submitted its first pre-Investigational New Drug (IND) application meeting request to the US Food and Drug Administration as part of the regulatory submission process.
PsyBio Therapeutics inducted into AdvisorShares Psychedelics ETF
PsyBio Therapeutics Corp said it has been included in the AdvisorShares Psychedelics Exchange Traded Fund (ETF). The intellectual property-driven, biotechnology company is currently developing novel, bespoke, and psycho-targeted therapeutics to potentially improve mental and neurological health.
Source: https://incomestatements.info
Category: Stock Reports